• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biol Chem . SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles

tetano

Editor, Senior Moderator
J Biol Chem


. 2020 Nov 19;jbc.RA120.016148.
doi: 10.1074/jbc.RA120.016148. Online ahead of print.
SARS-CoV-2 viral budding and entry can be modeled using BSL-2 level virus-like particles


Caroline B Plescia[SUP] 1 [/SUP], Emily A David[SUP] 1 [/SUP], Dhabaleswar Patra[SUP] 1 [/SUP], Ranjan Sengupta[SUP] 2 [/SUP], Souad Amiar[SUP] 3 [/SUP], Yuan Su[SUP] 1 [/SUP], Robert V Stahelin[SUP] 1 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in December 2019 in Wuhan, China and expeditiously spread across the globe causing a global pandemic. Research on SARS-CoV-2, as well as the closely related SARS-CoV-1 and MERS coronaviruses is restricted to BSL-3 facilities. Such BSL-3 classification make SARS-CoV-2 research inaccessible to the majority of functioning research laboratories in the US; this becomes problematic when the collective scientific effort needs to be focused on such in the face of a pandemic. However, a minimal system capable of recapitulating different steps of the viral life cycle without using the virus' genetic material could increase accessibility. In this work, we assessed the four structural proteins from SARS-CoV-2 for their ability to form virus-like particles (VLPs) from human cells to form a competent system for BSL-2 studies of SARS-CoV-2. Herein, we provide methods and resources of producing, purifying, fluorescently and APEX2-labeling of SARS-CoV-2 VLPs for the evaluation of mechanisms of viral budding and entry as well as assessment of drug inhibitors under BSL-2 conditions. These systems should be useful to those looking to circumvent BSL-3 work with SARS-CoV-2 yet study the mechanisms by which SARS-CoV-2 enters and exits human cells.

Keywords: Golgi; SARS-CoV-2; coronavirus; electron microscopy (EM); endoplasmic reticulum (ER); membrane bilayer; virology; virus; virus assembly; virus budding; virus entry; virus-like particle.
 
Back
Top Bottom